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InﬂammationAbstract Aim of the work: To study the mean platelet volume (MPV) in children with juvenile-
onset SLE (Jo-SLE), and whether MPV can be used as a biologic marker for disease activity or
ﬂare.
Patients and methods: Twenty-nine patients from the rheumatology outpatient clinic, Pediatric
Cairo University Hospitals and age 36 and gender matched healthy controls were included in the
study. The MPV was determined within 4 h of blood sampling in all study populations. Recent rou-
tine laboratory investigations for Jo-SLE patients were obtained. Disease activity was estimated
using SLE disease activity index (SLEDAI).
Results: 29 Jo-SLE patients had a mean age of 12.8 ± 2.9 years and disease duration of
3.5 ± 3 year. The most frequent clinical manifestations were photosensitivity, malar rash, followed
by arthritis and serositis. The MPV in Jo-SLE patients was 8.2 ± 2.1 femtoliters (fL) compared
with 5.6 ± 0.9 fL in healthy controls (p< 0.001). There was no signiﬁcant difference between
MPV in 18 active patients (8.3 ± 2.1 fL) compared to 11 patients with inactive disease
(8.1 ± 2.5 fL). Furthermore, there were no signiﬁcant correlations between the MPV and SLEDAI
score (r= 0.19, p= 0.33), or between MPV and other disease parameters routinely used to esti-
mate disease activity or ﬂare.
36 K. El-Garf et al.Conclusion: Results of the present study conﬁrm the association between MPV and inﬂamma-
tion, but do not support the use of MPV as an indicator for monitoring disease activity or ﬂare
in juvenile SLE. Further longitudinal studies with larger numbers of patients are warranted to
unveil the possibility of using MPV as a biologic marker of disease activity.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a chronic inﬂammatory
multi-system disease, characterized by diversity of Immuno-
logic abnormalities; most important is the production of a
number of antinuclear antibodies. SLE in children is essen-
tially the same disease as in adults with similar pathogenesis,
clinical manifestations, and immunologic ﬁndings. Although
juvenile SLE can occur at any age, it is more frequent after
5 years of age and is increasingly prevalent after the ﬁrst dec-
ade of life [1]. Juvenile onset SLE (Jo-SLE) is not uncommon
in Egypt [2]. In spite of similarity to adult’s disease, the care
and management of children with Jo-SLE is different from
that of adults in many aspects; because of the impact of the
chronic disease and drugs used in its management on both
physical and psychological growth and development of the
child. Over the last decades, survival of patients with juvenile
SLE has substantially improved. Prognostic factors that are
associated with unsatisfactory long-term outcome include:
poor compliance, neurologic complications, intercurrent infec-
tions and renal disease especially diffuse proliferative glomeru-
lonephritis [3,4]. One of the problems in management of both
adult and juvenile SLE is the lack of a sensitive and speciﬁc
biomarker that would respond to changes in disease activity
of SLE [5].
Products of activation of the circulating platelets play a key
role in the pathogenesis of vascular and inﬂammatory diseases
[6,7]. Platelets are anucleate cells and their size depends on the
degree of fragmentation of the megakaryocytes. Platelets with
increased size have a greater content of granules and can there-
fore exert their hemostatic and proinﬂammatory actions with
greater efﬁciency [8]. The mean platelet volume (MPV) is the
volume of the average circulating platelet in femtoliters (fL),
similar to the mean corpuscle volume (MCV) of red blood
cells. MPV is proposed to be an indicator of platelet function
and activation; and MPV has been investigated as an index of
disease activity in many rheumatic diseases [7,9–11].
The aim of the present study is to evaluate the concept of
the association of MPV and inﬂammation and to assess
whether MPV could be used as a marker of disease activity
in children with juvenile SLE.
2. Patients and methods
In this cross-sectional study, the mean platelet volume (MPV)
was determined in a total of 29 children with SLE and 36 con-
trol children. All patients were followed up in the pediatric
rheumatology clinic of Cairo University Hospitals. Diagnosis
of SLE was made in accordance with the American College
of Rheumatology (ACR) classiﬁcation criteria for SLE [12].
Assessment of disease activity was done at the same day ofestimation of MPV, using the SLE disease activity index
(SLEDAI) [13]. Patients have been classiﬁed on the basis of
their disease activity index into two activity categories: low
activity (SLEDAI < 10) and high activity (SLEDAI > 10).
None of our Patients had diabetes mellitus, hepatitis C virus,
recent thrombotic episode, hyperlipidemia or uncontrolled
hypertension. The control group consisted of 36 age and gen-
der matched healthy children. None of them had any comorbid
conditions. None of the study populations (patients and con-
trols) had received anticoagulant therapy or non-steroidal
anti-inﬂammatory drugs (NSAIDs) for 2 weeks before enroll-
ment in the study.
For MPV measurement, the blood samples were anticoag-
ulated by ethylenediamine tetraacetic acid [14], and then trea-
ted with rapid processing (within less than 4 h) and the
measurement and process were carried out according to stan-
dard laboratory practice for all patients and controls.
The study was approved by the ethics committee of the
Faculty of Medicine, Cairo University, and written informed
consent was received from at least one of the parents in all
cases.
Statistical analysis: Data analysis was performed through
Statistical Package of Social Sciences (SPSS) software program
for windows version 21. Data were expressed as mean and
standard deviation for quantitative variables and number
and percentage for qualitative ones. Comparison between
was performed through Chi square or Fisher’s exact test for
qualitative variables and independent sample t-test for quanti-
tative ones. Pearson correlation coefﬁcient was calculated to
signify the association of quantitative variables. P values less
than 0.05 considered signiﬁcant.
3. Results
Among the 29 patients, 21 (72.4%) were females and 8 (27.6%)
were males (F:M 2.6:1). Their age ranged between 4 and
13 years with a mean of 12.8 ± 2.9 years. Disease duration
ranged between 0.5 and 10 years with a mean of
3.5 ± 3.0 years. Table 1 summarizes the main clinical manifes-
tations and laboratory data of our patients. The most frequent
clinical manifestations were photosensitivity, malar rash, fol-
lowed by arthritis and serositis. Table 2 and Fig. 1 show the
signiﬁcant difference (p< 0.001) between MPV in children
with SLE (8.2 ± 2.1 fL) compared to that of the control group
(5.6 ± 0.9 fL). There was no signiﬁcant difference in the MPV
according to gender (8.4 ± 2.6 in males versus 8.1 ± 2.2 in
females; p= 0.7).
When SLE patients were classiﬁed into high (SLE-
DAI > 10) and low (SLEDAI < 10) disease activity, we
found no signiﬁcant difference between the MPV in 18
patients with high (8.3 ± 2.1 fL) compared to 11 with low
Table 1 Clinical and laboratory manifestations of 29 children
with Juvenile-onset systemic lupus erythematosus (Jo-SLE).
Manifestations
n (%)
Jo-SLE children
(n= 29)
Photosensitivity 19 (65.5)
Malar rash 17 (58.6)
Arthritis 12 (41.5)
Serositis 12 (41.5)
Neuropsychiatric 11 (37.9)
Oral ulcers 10 (34.5)
Vasculitis 5 (17.2)
Positive ANA 28 (96.6)
Positive anti ds-DNA 20 (69)
Leucopenia 12 (41.4)
Hemolytic anemia 6 (20.7)
Thrombocytopenia 10 (34.5)
Low C3 14 (48.3)
Albuminuria
+ 12 (41.5)
++ 5 (17.2)
+++ 2 (6.9)
High creatinine 6 (20.7)
Renal biopsy
Normal 11 (37.9)
Class II 5 (17.2)
Class III 6 (20.7)
Class IV 7 (24.1)
Class V 0 (0)
Jo-SLE: Juvenile-onset systemic lupus erythematosus, ANA:
Antinuclear antibody, ds-DNA: double stranded deoxy-ribonucleic
acid, C3: complement factor 3.
Table 3 Correlations between mean platelet volume (MPV)
and demographic and disease parameters in children with
Juvenile-onset systemic lupus erythematosus (Jo-SLE).
Parameter
in Jo-SLE children (n= 29)
MPV (fL)
r p Value
Current age (years) 0.07 0.73
Age at diagnosis (years) 0.08 0.68
Disease duration (years) 0.19 0.32
SLEDAI 0.19 0.33
Anti ds-DNA titer 0.02 0.93
Hemoglobin (g/dl) 0.34 0.07
Platelet count (·103/mm3) 0.16 0.40
TLC (·103/mm3) 0.01 0.97
ESR (mm/1st h) 0.23 0.23
C3 (mg/dl) 0.29 0.13
Creatinine (mg/dl) 0.22 0.26
Albuminuria 0.21 0.26
Jo-SLE: Juvenile-onset systemic lupus erythematosus, MPV: mean
platelet volume, SLEDAI: systemic lupus erythematosus disease
activity index, ds-DNA: double stranded deoxy-ribonucleic acid,
TLC: total leukocytic count, ESR: erythrocyte sedimentation rate,
C3: complement factor 3.
Mean platelet volume as marker in juvenile SLE children 37(8.1 ± 2.5 fL) disease activity. Statistical correlation of the
demographic and disease parameters including SLEDAI score
with the MPV showed no signiﬁcance (Table 3, Fig. 2).
4. Discussion
Most of the inﬂammatory rheumatic diseases are characterized
by inﬂammation and variable degrees of vascular involvement.
Recent literature indicated that MPV may be used as a marker
of inﬂammation, disease activity and efﬁcacy of therapy in sev-
eral chronic inﬂammatory diseases [6]. High-grade inﬂamma-
tion in active rheumatoid arthritis (RA) was accompanied
with a decreased MPV, possibly due to increased consumption
of platelets at sites of rheumatoid inﬂammation [7]. A reverse
shift of MPV results from suppression of inﬂammation by dis-
ease modifying drugs and anti-TNF-alpha agents [15]. OtherTable 2 Mean platelet volume (MPV) in children with
Juvenile-onset systemic lupus erythematosus (Jo-SLE) and
control group.
Jo-SLE
(n= 29)
Control
(n= 36)
p Value
MPV (fL) 8.2 ± 2.1 5.6 ± 0.9 <0.001
Jo-SLE: Juvenile-onset systemic lupus erythematosus, MPV: mean
platelet volume. Bold value is signiﬁcantly different at p< 0.05.studies showed increased MPV in patients with RA and posi-
tive correlation with disease activity estimated by DAS28 [9].
Hypertension was a strong predictor of high MPV in rheuma-
toid patients [16]. There were controversial ﬁndings as regards
the MPV in ankylosing spondylitis [7,17] while it was reported
to be signiﬁcantly elevated in SSc patients [18]. In children with
familial Mediterranean fever (FMF) the MPV values were
found to be signiﬁcantly higher compared with the controls
[19,20] and was reported to be decreased in FMF patients dur-
ing attacks compared to the attack-free periods [21]. MPV has
also been investigated in Behcet’s disease (BD), it was shownFigure 1 Mean platelet volume (MPV) in children with Juvenile-
onset systemic lupus erythematosus (Jo-SLE) compared to control
children. *Signiﬁcantly different from control (p< 0.001).
Figure 2 Correlation between mean platelet volume (MPV) and
systemic lupus erythematosus disease activity index (SLEDAI) in
children with Juvenile-onset SLE (Jo-SLE).
38 K. El-Garf et al.that an increase in MPV may indicate the presence of venous
thrombosis, but no signiﬁcant difference was found in MPV
between patients with active BD compared to inactive disease
[22]. In a previous study, signiﬁcantly lower levels of vitamin D
was found in Jo-SLE patients [23] and interestingly vitamin D
deﬁciency was reported to be strongly associated with an
increased MPV [24].
The present study included 29 juvenile SLE patients.
Thrombocytopenia was found in 34.5% of the cases. The fre-
quency of thrombocytopenia and of the other laboratory fea-
tures, were comparable to the frequency reported in another
study on Egyptian juvenile SLE children [25].
SLE is an autoimmune disease characterized by abundant
production of autoantibodies. Platelet activation, release of
vasoactive and thrombogenic molecules, and accelerated
atherosclerosis are well known factors that are involved in
the pathogenesis and morbidity of the disease [26]. Antibod-
ies targeting platelet glycoproteins IIb/IIIa and IV were iden-
tiﬁed and thought to play a role in thrombocytopenia in SLE
[27]. One of the earliest studies of MPV using two different
hematology analyzers demonstrated low MPV (<7.2 fL) in
14.3% and 65.7% in patients with SLE, mostly at active
stage. However, no conclusion was made in this study, since
there was no proper calibration and timing of blood sample
processing [28]. A recent study on the MPV in juvenile
SLE demonstrated that MPV signiﬁcantly increased com-
pared to healthy children; in addition, an increase in MPV
levels might be an indicator of worsening of childhood-
onset SLE disease activity [11]. In the same study, the authors
assumed that MPV might be a more accurate indicator for
monitoring the disease activity than ESR or C3 estimation.
The aim of the present study is to conﬁrm the concept of
the association of MPV and inﬂammation and to assess
whether MPV could be used as a marker of disease activity
in children with juvenile SLE.
The present study demonstrated that MPV signiﬁcantly
increased (p< 0.001) in patients with juvenile SLE (8.2 ±
2.1 fL) when compared to healthy children (5.6 ± 0.9 fL); a
ﬁnding that conﬁrms the previously reported data of
signiﬁcant increase of MPV in juvenile-onset SLE [11]. Diseaseactivity in our patients was estimated using the SLEDAI score
[13,29]. Due to the relatively small number of the patients in
the study, we classiﬁed our patients into two activity cate-
gories; inactive or mildly active disease (SLEDAI 6 10), high
disease active (SLEDAI > 10). There was no signiﬁcant differ-
ence in the MPV between 18 juvenile SLE patients with low
disease activity and 11 with active disease. This was also con-
ﬁrmed by the absence of signiﬁcant correlation (r= 0.19,
p= 0.33) between the SLEDAI score and the MPV in our
patients (Fig. 1). The F:M ratio in this study was 2.6:1 and this
was in agreement to the ratio presented in another study on
Egyptian Jo-SLE and was 2.7:1 [30]. There was no signiﬁcant
difference in the MPV according to gender.
In addition, there was no signiﬁcant correlation between
the MPV and demographic data (age, age of onset, disease
duration), platelet count, or other parameters commonly used
as indicators of disease activity in SLE e.g. erythrocyte sedi-
mentation rate (ESR), anti-double stranded (anti-ds DNA)
titer, complement-3 (C3), creatinine or the level of albuminuria
(Table 3). These results were not in agreement with the previ-
ous study on juvenile SLE [11] that suggested using the MPV
as a more accurate indicator for monitoring the disease activity
than ESR or C3 level. Interestingly, it has recently been
reported that the MPV was signiﬁcantly higher in anti-
phospholipid syndrome (APS) patients especially during
thrombotic events [31].
In conclusion, this study demonstrated that MPV is signiﬁ-
cantly elevated in children with juvenile SLE. Moreover, juve-
nile SLE patients are susceptible to increased platelet
activation and increased MPV values that contribute to the
systemic inﬂammatory response of the disease. However, the
results of the study cannot propose the use of MPV as an indi-
cator of disease activity or ﬂare in juvenile SLE. Further mul-
ticenter studies with larger numbers of patients with juvenile
and adult SLE patients are warranted to unveil the controversy
in the literature as regards using MPV as a biologic marker for
disease activity in SLE.
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